Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MRES looking good with the volume.
1 day big volume the next day nothing?
Break loose soon.
Imho
With tax loss selling over we will see
APSI start to bloom once again.
Huge volume for MRES at least 7x's , and a lot of day left.
Take out the seller, and then Up we Go.
MRES .0103
YES, huge volume for MRES
Take out the seller, and then Up we Go.
MRES on sale now.
I was able to pick up a few @ .0082
Added.
Here we going up now REVERSAL.
Now, nobody will get anything. Everyone gets , jack.
I never can understand that.
I would think there is 2 sides to this story.
Some where in the middle the truth lies.
There is much that we'll never know.
It would be nice to get an update someday.
Maybe recovery some $
Smartest post I have read in days.
Post of the day award too.
I have had them on ignore for years.
I Picked up 20k today at .0355 and .0354.
First Buy of anything in quit some time "added"
XCRT
I am off to see the wizard, the wonderful wizard of Oz.
We are on the yellow brick road here.
Wow up 100%. Congratulations to DIGITECH.
Ausome Contest
Maybe next time I will do better than Down 80%. Ya-think?
Again thank you sskillz1
NHMD fantastic. Thanks for your thoughts.
Agree
Excellent post Sterling. This post deserves a big sticky for sure. I'm excited as hell and can't wait for this to close this week! Thank You!!
Reading this board, and many others here on ihub
I have come to the conclusion
I know now why the World is so screwed up.
MRES
https://www.worldcoffeeportal.com/Latest/News/2021/May/Rand-Capital-Coffee-aspires-to-scale-Starbucks-acr
Rand Capital Coffee aspires to scale Starbucks across Africa
Rand Capital Coffee CEO Adrian Maizey has outlined his company’s vision to grow Starbucks’ presence beyond South Africa and across the African continent
M2Bio is set to collaborate with Rand Capital Coffee within the premises. Rand Capital, founded in 2010, oversees and manages over 70 premium coffee cafes across Southern Africa. The offices are at 1515 Palisades Drive, Pacific Palisades, CA.
Michael Sachar, CEO of M2Bio Sciences Food and Beverage, expressed excitement about the expansion, stating, "We are ecstatic about opening the M2Bio Sciences Food and Beverage offices in Los Angeles. Having a solid base in California allows us to gain a foothold on the West Coast as our rollout for North American distribution for 2024 gains momentum. We have seen phenomenal growth in the food division and are excited to share our premium health-centric products with new partners and consumers."
https://www.worldcoffeeportal.com/Latest/News/2021/May/Rand-Capital-Coffee-aspires-to-scale-Starbucks-acr
Rand Capital Coffee aspires to scale Starbucks across Africa
Rand Capital Coffee CEO Adrian Maizey has outlined his company’s vision to grow Starbucks’ presence beyond South Africa and across the African continent
MRES: M2Bio Sciences Marks Milestone Expansion with Launch of Los Angeles Office
Press Release | 11/14/2023
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 14, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update:
M2Bio Sciences Food & Beverage strategically expands its presence by opening offices in Los Angeles, California. This move aims to broaden the distribution of Liviana™ and Medspresso™ products within the United States, aligning with the company's global commitment to providing healthy and trusted food products backed by evidence-based clinical science.
M2Bio is set to collaborate with Rand Capital Coffee within the premises. Rand Capital, founded in 2010, oversees and manages over 70 premium coffee cafes across Southern Africa. The offices are at 1515 Palisades Drive, Pacific Palisades, CA.
Michael Sachar, CEO of M2Bio Sciences Food and Beverage, expressed excitement about the expansion, stating, "We are ecstatic about opening the M2Bio Sciences Food and Beverage offices in Los Angeles. Having a solid base in California allows us to gain a foothold on the West Coast as our rollout for North American distribution for 2024 gains momentum. We have seen phenomenal growth in the food division and are excited to share our premium health-centric products with new partners and consumers."
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES."
Publicly traded Company (OTC Pink: MRES)
www.m2bio.co
MRES News
African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair
Press Release | 11/03/2023
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 3, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update:
The Annual Biomedical Research & Innovation Platform Symposium took place on the 16 th & 17 th of October 2023, with Prof Vinesh Maharaj as the first keynote speaker of this two-day event that delved into an electrifying exploration of innovation, tradition, and groundbreaking potential in the realm of biomedicine. Professor Maharaj holds the esteemed position of Deputy Dean of Research and Postgraduate Education at the University of Pretoria and Chair of the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research .
Professor Maharaj's presentation guides us on a historical journey of traditional plant-based medicine. It demonstrates how modern scientific insights can elucidate the mechanisms of action of various plants, fostering a collaborative partnership between traditional healers and conventional medical practitioners. Remarkably, more than half of all pharmaceutical drugs trace their origins to natural compounds, with 52% of medications being plant-derived. South Africa, boasting 24,000 plant species, ranks third globally in biodiversity. Notably, an impressive 20% of these species are unique to South Africa, found nowhere else in the world. To access the recording, please click here .
Maharaj highlights several well-known pharmaceuticals derived from plants, including Paclitaxel (PTX, used in cancer treatment), Quinine (an anti-malarial drug), Aspirin (with anti-inflammatory, analgesic, and antipyretic properties), and Morphine (an effective analgesic). Harnessing plants for drug development necessitates the identification of their active ingredients, a challenging task due to the multitude of compounds found in plants. This intricate process can take anywhere from 12 to 24 months to isolate, purify, and determine the structure of a single compound. In perspective, developing one FDA-approved drug typically demands screening through 10,000 compounds and may span several years.
The proposed solution to making this process more efficient involves creating a natural product library and employing artificial intelligence for efficient screening, a concept introduced at the 22:57-minute mark. The University of Pretoria, equipped with 11,000 plant samples, is actively working on establishing a comprehensive database. Furthermore, they have devised a high-throughput extraction method for screening, enabling the retrieval of samples from a robotic storage database for the subsequent generation of biological assays, facilitating the screening and analysis of potentially beneficial compounds.
At the 31:18-minute timestamp, Professor Vinesh discusses their compelling findings that demonstrate the efficacy of African ginger ( Siphonochilus aethiopicus ) against SARS-CoV-2, encompassing the Wuhan, delta, and beta variants, as well as influenza viruses. These effects were observed at concentrations comparable to standard control drugs used in respective assays[1]. Respiratory viral diseases, including COVID-19 and influenza, threaten global health, societal stability, and the economy. Despite the availability of numerous vaccines and treatments for these conditions, seasonal influenza alone still accounts for an estimated 3 to 5 million cases of severe illness and approximately 290,000 to 650,000 respiratory-related fatalities each year on a global scale. Consequently, there is a pressing need for the discovery and development of a more cost-effective and productive treatment regimen, ideally one with dual activity against these respiratory viral diseases, given the likelihood of co-infections[2]. The University of Pretoria has recently filed a patent for using African ginger in the fight against COVID-19, marking one of the leading research initiatives within M2Bio Sciences, an entity driven by artificial intelligence and machine learning, as highlighted at the 39:10-minute mark.
"Professor Vinesh Maharaj's keynote presentation during the Annual Biomedical Research & Innovation Platform Symposium illuminated the potent antiviral properties of African ginger in combating both influenza and SARS-CoV-2. This revelation was underscored by the exceptional synergy of integrating natural remedies and artificial intelligence. Collectively, our findings unveil a promising trajectory for healthcare innovation, where the harmonious convergence of traditional approaches and cutting-edge technology is poised to have a profound impact on life-saving interventions," articulated Jeff Robinson, Chief Executive Officer of M2Bio Sciences.
Professor Vinesh Maharaj, a distinguished figure in Research and Postgraduate Education within the Faculty of Natural and Agricultural Sciences, is a natural product chemist with expertise in discovering novel drug candidates derived from biodiversity samples. His primary objective centers around establishing a unique repository of natural products, encompassing a remarkable 10,000 plant specimens. This repository, a pioneering African endeavor, is the foundation for an innovative library. These plant samples are adeptly transformed into high throughput screening formats, primed for rigorous biological assessments to combat diseases like HIV, malaria, cancer, and COVID-19.
Through his efforts, he secured funding from the Department of Science and Innovation (DSI) to institute this pivotal platform, thus ensuring the availability of these invaluable resources to the national innovation system. This infrastructure is well-appointed with cutting-edge hyphenated analytical equipment, instrumental in the comprehensive chemical characterization of the library.
Furthermore, Professor Maharaj is the Chair of the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research, overseeing the natural product research endeavors conducted at the university on behalf of M2Bio Sciences.
To access the recording, please click here .
[1] https://repository.up.ac.za/handle/2263/78055 , Provisional Patent - Ref No.PA177413/P 1 and SA Patent Application No. 2022/11187 (Inventors - V. Maharaj, L. Invernizzi and P. Moyo).[2] https://journals.asm.org/doi/10.1128/jvi.01873-21
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES".
Publicly traded Company (OTC Pink: MRES)
www.m2bio.co
MRES News
African Ginger Patented for Influenza and SARS-CoV-2 Treatment: Insights from M2Bio Sciences Research Chair
Press Release | 11/03/2023
CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / November 3, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update:
The Annual Biomedical Research & Innovation Platform Symposium took place on the 16 th & 17 th of October 2023, with Prof Vinesh Maharaj as the first keynote speaker of this two-day event that delved into an electrifying exploration of innovation, tradition, and groundbreaking potential in the realm of biomedicine. Professor Maharaj holds the esteemed position of Deputy Dean of Research and Postgraduate Education at the University of Pretoria and Chair of the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research .
Professor Maharaj's presentation guides us on a historical journey of traditional plant-based medicine. It demonstrates how modern scientific insights can elucidate the mechanisms of action of various plants, fostering a collaborative partnership between traditional healers and conventional medical practitioners. Remarkably, more than half of all pharmaceutical drugs trace their origins to natural compounds, with 52% of medications being plant-derived. South Africa, boasting 24,000 plant species, ranks third globally in biodiversity. Notably, an impressive 20% of these species are unique to South Africa, found nowhere else in the world. To access the recording, please click here .
Maharaj highlights several well-known pharmaceuticals derived from plants, including Paclitaxel (PTX, used in cancer treatment), Quinine (an anti-malarial drug), Aspirin (with anti-inflammatory, analgesic, and antipyretic properties), and Morphine (an effective analgesic). Harnessing plants for drug development necessitates the identification of their active ingredients, a challenging task due to the multitude of compounds found in plants. This intricate process can take anywhere from 12 to 24 months to isolate, purify, and determine the structure of a single compound. In perspective, developing one FDA-approved drug typically demands screening through 10,000 compounds and may span several years.
The proposed solution to making this process more efficient involves creating a natural product library and employing artificial intelligence for efficient screening, a concept introduced at the 22:57-minute mark. The University of Pretoria, equipped with 11,000 plant samples, is actively working on establishing a comprehensive database. Furthermore, they have devised a high-throughput extraction method for screening, enabling the retrieval of samples from a robotic storage database for the subsequent generation of biological assays, facilitating the screening and analysis of potentially beneficial compounds.
At the 31:18-minute timestamp, Professor Vinesh discusses their compelling findings that demonstrate the efficacy of African ginger ( Siphonochilus aethiopicus ) against SARS-CoV-2, encompassing the Wuhan, delta, and beta variants, as well as influenza viruses. These effects were observed at concentrations comparable to standard control drugs used in respective assays[1]. Respiratory viral diseases, including COVID-19 and influenza, threaten global health, societal stability, and the economy. Despite the availability of numerous vaccines and treatments for these conditions, seasonal influenza alone still accounts for an estimated 3 to 5 million cases of severe illness and approximately 290,000 to 650,000 respiratory-related fatalities each year on a global scale. Consequently, there is a pressing need for the discovery and development of a more cost-effective and productive treatment regimen, ideally one with dual activity against these respiratory viral diseases, given the likelihood of co-infections[2]. The University of Pretoria has recently filed a patent for using African ginger in the fight against COVID-19, marking one of the leading research initiatives within M2Bio Sciences, an entity driven by artificial intelligence and machine learning, as highlighted at the 39:10-minute mark.
"Professor Vinesh Maharaj's keynote presentation during the Annual Biomedical Research & Innovation Platform Symposium illuminated the potent antiviral properties of African ginger in combating both influenza and SARS-CoV-2. This revelation was underscored by the exceptional synergy of integrating natural remedies and artificial intelligence. Collectively, our findings unveil a promising trajectory for healthcare innovation, where the harmonious convergence of traditional approaches and cutting-edge technology is poised to have a profound impact on life-saving interventions," articulated Jeff Robinson, Chief Executive Officer of M2Bio Sciences.
Professor Vinesh Maharaj, a distinguished figure in Research and Postgraduate Education within the Faculty of Natural and Agricultural Sciences, is a natural product chemist with expertise in discovering novel drug candidates derived from biodiversity samples. His primary objective centers around establishing a unique repository of natural products, encompassing a remarkable 10,000 plant specimens. This repository, a pioneering African endeavor, is the foundation for an innovative library. These plant samples are adeptly transformed into high throughput screening formats, primed for rigorous biological assessments to combat diseases like HIV, malaria, cancer, and COVID-19.
Through his efforts, he secured funding from the Department of Science and Innovation (DSI) to institute this pivotal platform, thus ensuring the availability of these invaluable resources to the national innovation system. This infrastructure is well-appointed with cutting-edge hyphenated analytical equipment, instrumental in the comprehensive chemical characterization of the library.
Furthermore, Professor Maharaj is the Chair of the M2Bio Sciences Discovery Centre for AI-Driven Phytomedicine Research, overseeing the natural product research endeavors conducted at the university on behalf of M2Bio Sciences.
To access the recording, please click here .
[1] https://repository.up.ac.za/handle/2263/78055 , Provisional Patent - Ref No.PA177413/P 1 and SA Patent Application No. 2022/11187 (Inventors - V. Maharaj, L. Invernizzi and P. Moyo).[2] https://journals.asm.org/doi/10.1128/jvi.01873-21
About Institute of Biomedical Research Corp./ DBA M2Bio Sciences
Institute of Biomedical Research Corp is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids, medical psilocybin and mental health therapeutic research powered by artificial intelligence, and evidence-based sustainable products and solutions that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, Liviana™ brands as well as artificial intelligence-powered nutrition products and solutions under the M2Biome brand. In addition, our research and clinical trials with psilocybin are aimed at new therapies to help patients suffering from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies such as artificial intelligence.
The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol "MRES".
Publicly traded Company (OTC Pink: MRES)
www.m2bio.co
1 Million Bid @ .026.
Substantial
Added at .01 this morning.
My order is in to add a few more, but
sellers don't want to go that low.
Watching and waiting.
MRES
Fantastic.
Looks like the Ask ask has really thinned out
compared to the last few days.
Hold for Gold now.
Added 13's
And went on a iggy spree.
Left only the people with a brain.
Thanks for the shares.
I have not needed the $$$ for 2 years now.
So holding here too to see what happens.
SOLInaires all the way .
Steph 1971 Thanks for keeping us informed ,
Happy faces all around.😋
Fantastic.
Taken from PR
Maybe they got them I hope soVHHI and the CareClix Group of Companies have audited financial statements for each
of the fiscal years ended December 31, 2019. 3020, 2021 and 2022..
Also This
An analysis of the MyGuardianDoc™ business model by an independent sales and
marketing company projects that that company alone can generate more than a million subscribers within the first
12 months, or a total monthly recurring revenue of more than $25 million.
VHHI and the CareClix Group of Companies have audited financial statements for each
of the fiscal years ended December 31, 2019. 3020, 2021 and 2022.
Am I understanding this right???
The deal went threw.
WPF Holdings has chosen to make healthcare one of the first market sectors it develops under the Vezbi Super App
and has made agreements to acquire in whole or part several other healthcare companies. The healthcare industry
is one of the largest industries in the United States and we believe the Vezbi Super App can simplify and integrate
medical information and services for consumers. Which will, in turn, help medical providers, insurers and related
companies be able to focus more on patient care and remain bogged down by the technical hang-ups that have
plagued the industry for years. Through the Vezbi Super App and the power of its cohesive integrations, we will be
able to break through the “log jam” that the healthcare industry has struggled with as it tries to adapt to our growing
digital world.
VHHI currently operates as a global virtual healthcare ecosystem centered around the CareClix Group of companies
to provide the complete telehealth solution. The CareClix Group of companies consists of: CareClix Inc., CareClix
Services, Inc., MyCareClix, Inc., CareClix Network PA and CareClix RPM. Inc., which are each a wholly owned
subsidiary of VHHI”), Inc. VHHI and the CareClix Group of Companies have audited financial statements for each
of the fiscal years ended December 31, 2019. 3020, 2021 and 2022.
The CareClix Group
We acquired the CareClix Group in order to expand into the telemedicine and medical software services industry.
The group of companies under the CareClix Group will operate as our wholly owned subsidiaries and include a
telemedicine medical services company, a direct-to-consumer company, a software-as-a- platform company, and
an RPM (remote patient monitoring) company.
CARECLIX, INC.
CareClix Inc is a cloud-based enterprise telehealth software development company which develops and supports
the CareClix® Anywhere Virtual Care Management Platform. CareClix Inc mission is to improve healthcare
delivery through increased ease, interoperability, data management, and patient engagement. The CareClix®
Anywhere Telemedicine platform was first developed in 2012 by practicing physicians; and development continues
to be overseen by active licensed physicians. This differentiates CareClix® from its competitors. Our doctor focused
approach drives our success in creating a suite of tools that improve care access, coordination, cost and quality. The
CareClix® platform seamlessly and modularly integrates popular EHRs, claims systems, e-prescription, diagnostic
laboratories, payer eligibility, medical devices and patient education. Currently the CareClix® virtual care platform
has been recognized worldwide as one of the most complete telehealth platforms for medical service providers. It
has been ranked by KLAS and was selected as the premiere virtual care platform by the New York Medical Society,
Dallas Medical Society, Northern Virginia Medical Society, San Bernadino Medical Society, and International
Medical Society. CareClix, Inc provides the technical platform for the CareClix Group of companies and sells it as
Software-As-A-Service (SaaS) globally.
CARECLIX SERVICES, INC.
CareClix Services, Inc is a virtual healthcare delivery company. CareClix Services Inc combines the CareClix
software with our multinational, multispecialty medical network to offer virtual healthcare services to a wide variety
of health care services such as insurers, employers, affinity groups, healthcare systems, provider groups and
independent physicians. CareClix Services, Inc is a leader in custom multinational virtual medicine. Our customers
mix-and-match from our portfolio of technologies, medical services, and integrations. CareClix® also matches the
transparency to our customers or partner’s comfort level allowing them to seamlessly grow their practice, their
brand, and their revenue. CareClix Services is trusted by some of the best names in healthcare with more than 20
million individuals in the U.S. and over 35 other countries having access to CareClix' platform or services. Medical
3
services are provided by our affiliate medical group CareClix Network PA. CareClix Network PA is a wellestablished network of primary care and specialist physicians, and hospitals – including mental health – both in the
US and internationally.
MYCARECLIX, INC.
My CareClix, Inc operates as a direct-to-consumer healthcare delivery company providing affordable care with
concentration on patient safety and healthcare equity. MyCareClix is launching under the brand MyGuardianDoc™.
™subscription fee, consumers in the US can have access to these services. We believe MyGuardianDoc™ can help
reduce the healthcare equity gap and improve patient safety by providing a medical chaperone in an affordable and
convenient way. MyCareClix has formed a Patient Safety and Care Equity Counsel whose purpose is to help relieve
the pains caused by the current healthcare system leading to improved healthcare outcomes. By providing our
Subscriber Households access to a physician, they can receive guidance, oversight, and care from a provider who
has been trained to be sensitive to the needs of societal and racial minorities. Integration of the MyGuardianDoc™
medical delivery and medical chaperone system with the Vezbi Super App represents a potentially revolutionary
innovation in medical care. An analysis of the MyGuardianDoc™ business model by an independent sales and
marketing company projects that that company alone can generate more than a million subscribers within the first
12 months, or a total monthly recurring revenue of more than $25 million.
CARECLIX RPM, INC.
CareClix RPM, Inc will develop and support technologies and services related to expanding the reach of medical
services through Remote Patient Monitoring and Remote Therapeutic Monitoring. CareClix RPM will distribute
and monitor FDA approved healthcare devices for remote patient monitoring, remote therapeutic monitoring, and
chronic care management. Utilizing the CareClix platform to track and report monitored patient data, CareClix
RPM, Inc will create turnkey solutions for providers seeking to start or expand their remote patient monitoring, data
integration, remote therapeutic monitoring, or chronic care management programs. Anticipated to begin the second
quarter of 2023, CareClix RPM will procure and distribute devices and offer a multi-lingual patient engagement
team with qualified medical oversight and thorough reporting for billing and care plan administration.
CARECLIX NETWORK, PA is a Florida professional medical association affiliated with CareClix, Inc.. which has
contracted with medical professionals to provide virtual healthcare consultations to patients on a global basis.
Nearing the High of the day again.
MONI
Very Nice. We may be in good Hands.
TY
I have tried that already.
We seem to pick the wrong ones.
We should have picked that other one is my story.
Still holding here though.
I have upgraded to a eclectic compressor.
Volume pouring in .
Where's the News?
1 mil. Bid @ .0275 nice.
$27,500 dollars.
Its coming closer.